{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:01:56Z","timestamp":1793394116637,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with higher-risk (HR) myelodysplastic syndrome (MDS), ineligible for allogeneic hematopoietic stem cell transplantation (alloHSCT), require prompt therapeutic interventions, such as treatment with hypomethylating agents (HMAs) to restore normal DNA methylation patterns, mainly of oncosuppressor genes, and consequently to delay disease progression and increase overall survival (OS). However, response assessment to HMA treatment relies on conventional methods with limited capacity to uncover a wide spectrum of underlying molecular events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We implemented liquid chromatography-tandem mass spectrometry (LC-MS\/MS) to assess 5\u2019 methyl-2\u2019 deoxycytidine (5mdC), 5\u2019 hydroxy-methyl-2\u2019-deoxycytidine (5hmdC) levels and global adenosine\/thymidine ([dA]\/[T]) ratio in bone marrow aspirates from twenty-one HR MDS patients, pre- and post-HMA treatment. Additionally, targeted methylation analysis was performed by interpretation of NGS-methylation (MeD-seq) data obtained from the same patient cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>LC\/MS-MS analysis revealed a significant hypomethylation status in responders (Rs), already established at baseline and a trend for further DNA methylation reduction post-HMA treatment. Non-responders (NRs) reached statistical significance for DNA hypomethylation only post-HMA treatment. The 5hmdC epigenetic mark was approximately detected at 37.5\u201340% among NRs and Rs, implying the impairment of the natural active demethylation pathway, mediated by the ten-eleven (TET) 5mdC dioxygenases. R and NR subgroups displayed a [dA]\/[T] ratio\u2009&lt;\u20091 (0.727\u2009\u2212\u20090.633), supporting high frequences of 5mdC transition to thymidine. Response to treatment, according to whole genome MeD-seq data analysis, was associated with specific, scattered hypomethylated DMRs, rather than presenting a global effect across genome. MeD-seq analysis identified divergent epigenetic effects along chromosomes 7, 9, 12, 16, 18, 21, 22, X and Y. Within statistically significant selected chromosomal bins, genes encoding for proteins and non-coding RNAs with reversed methylation profiles between Rs and NRs, were highlighted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Implementation of powerful analytical tools to identify the dynamic DNA methylation changes in HR MDS patients undergoing HMA therapy demonstrated that LC-MS\/MS exerts high efficiency as a broad-based but rapid and cost-effective methodology (compared to MeD-seq) to decode different perspectives of the epigenetic background of HR MDS patients and possess discriminative efficacy of the response phenotype to HMA treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10020-025-01123-7","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T10:09:31Z","timestamp":1739527771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Integrating advanced analytical methods to assess epigenetic marks affecting response to hypomethylating agents in higher risk myelodysplastic syndrome"],"prefix":"10.1186","volume":"31","author":[{"given":"Theodoros","family":"Nikolopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Bochalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Chatzilygeroudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Chondrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Dereki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Athanasopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Zafeiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos","family":"Bourikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George P.","family":"Patrinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argiris","family":"Symeonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argyro","family":"Sgourou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"1123_CR5","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.3390\/curroncol31050175","volume":"31","author":"R Abdulbaki","year":"2024","unstructured":"Abdulbaki R, Pullarkat ST. A brief overview of the molecular landscape of myelodysplastic neoplasms. Curr Oncol. 2024;31:2353\u201363. https:\/\/doi.org\/10.3390\/curroncol31050175","journal-title":"Curr Oncol"},{"key":"1123_CR3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"1123_CR15","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1046\/j.1365-2141.2003.04194.x","volume":"120","author":"WY Au","year":"2003","unstructured":"Au WY, Fung A, Man C, Ma SK, Wan TS, Liang R, Kwong YL. Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations. Br J Haematol. 2003;120:1062\u20135. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04194.x","journal-title":"Br J Haematol"},{"key":"1123_CR13","doi-asserted-by":"publisher","first-page":"6874","DOI":"10.1038\/s41598-023-33932-3","volume":"13","author":"N Besselink","year":"2023","unstructured":"Besselink N, Keijer J, Vermeulen C, Boymans S, de Ridder J, van Hoeck A, Cuppen E, Kuijk E. The genome-wide mutational consequences of DNA hypomethylation. Sci Rep. 2023;13:6874. https:\/\/doi.org\/10.1038\/s41598-023-33932-3","journal-title":"Sci Rep"},{"key":"1123_CR35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1101\/gr.222885.117","volume":"28","author":"R Boers","year":"2018","unstructured":"Boers R, Boers J, de Hoon B, Kockx C, Ozgur Z, Molijn A, van Laven IW, Gribnau J J. Genome-wide DNA methylation profiling using the methylation-dependent restriction enzyme LpnPI. Genome Res. 2018;28:88\u201399. https:\/\/doi.org\/10.1101\/gr.222885.117","journal-title":"Genome Res"},{"key":"1123_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13148-021-01002-y","volume":"13","author":"M Cabezon","year":"2021","unstructured":"Cabezon M, Malinverni R, Bargay J, Xicoy B, Marce S, Garrido A, Tormo M, Arenillas L, Coll R, Borras J, et al. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival. Clin Epigenetics. 2021;13:9. https:\/\/doi.org\/10.1186\/s13148-021-01002-y","journal-title":"Clin Epigenetics"},{"key":"1123_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13148-024-01687-x","volume":"16","author":"T Chatzilygeroudi","year":"2024","unstructured":"Chatzilygeroudi T, Chondrou V, Boers R, Siamoglou S, Athanasopoulou K, Verigou E, Gribnau J, Alexis S, Labropoulou V, Kourakli A, et al. Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk MDS and CMML. Clin Epigenetics. 2024;16:79. https:\/\/doi.org\/10.1186\/s13148-024-01687-x","journal-title":"Clin Epigenetics"},{"key":"1123_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u201325. https:\/\/doi.org\/10.1182\/blood-2005-10-4149","journal-title":"Blood"},{"key":"1123_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13036-017-0052-9","volume":"11","author":"B Chowdhury","year":"2017","unstructured":"Chowdhury B, Cho IH, Irudayaraj J. Technical advances in global DNA methylation analysis in human cancers. J Biol Eng. 2017;11:10. https:\/\/doi.org\/10.1186\/s13036-017-0052-9","journal-title":"J Biol Eng"},{"key":"1123_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1741-7007-11-4","volume":"11","author":"TA Clark","year":"2013","unstructured":"Clark TA, Lu X, Luong K, Dai Q, Boitano M, Turner SW, He C, Korlach J. Enhanced 5-methylcytosine detection in single-molecule, real-time sequencing via Tet1 oxidation. BMC Biol. 2013;11:4. https:\/\/doi.org\/10.1186\/1741-7007-11-4","journal-title":"BMC Biol"},{"key":"1123_CR41","doi-asserted-by":"publisher","unstructured":"Cook MR, Karp JE, Lai C. The spectrum of genetic mutations in myelodysplastic syndrome: should we update prognostication? EJHaem. 2022;3:301\u201313. https:\/\/doi.org\/10.1002\/jha2.317","DOI":"10.1002\/jha2.317"},{"key":"1123_CR50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/BF02170221","volume":"8","author":"D Elson","year":"1952","unstructured":"Elson D, Chargaff E. On the desoxyribonucleic acid content of sea urchin gametes. Experientia. 1952;8:143\u20135. https:\/\/doi.org\/10.1007\/BF02170221","journal-title":"Experientia"},{"key":"1123_CR12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41586-022-04785-z","volume":"606","author":"MA Fabre","year":"2022","unstructured":"Fabre MA, de Almeida JG, Fiorillo E, Mitchell E, Damaskou A, Rak J, Orru V, Marongiu M, Chapman MS, Vijayabaskar MS, et al. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature. 2022;606:335\u201342. https:\/\/doi.org\/10.1038\/s41586-022-04785-z","journal-title":"Nature"},{"key":"1123_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(09)70003-8","journal-title":"Lancet Oncol"},{"key":"1123_CR47","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ygeno.2014.08.017","volume":"104","author":"G Ficz","year":"2014","unstructured":"Ficz G, Gribben JG. Loss of 5-hydroxymethylcytosine in cancer: cause or consequence? Genomics. 2014;104:352\u20137. https:\/\/doi.org\/10.1016\/j.ygeno.2014.08.017","journal-title":"Genomics"},{"key":"1123_CR14","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/febs.15722","volume":"289","author":"EE Grundy","year":"2022","unstructured":"Grundy EE, Diab N, Chiappinelli KB. Transposable element regulation and expression in cancer. FEBS J. 2022;289:1160\u201379. https:\/\/doi.org\/10.1111\/febs.15722","journal-title":"FEBS J"},{"key":"1123_CR48","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1038\/s41467-021-24425-w","volume":"12","author":"B He","year":"2021","unstructured":"He B, Zhang C, Zhang X, Fan Y, Zeng H, Liu J, Meng H, Bai D, Peng J, Zhang Q, et al. Tissue-specific 5-hydroxymethylcytosine landscape of the human genome. Nat Commun. 2021;12:4249. https:\/\/doi.org\/10.1038\/s41467-021-24425-w","journal-title":"Nat Commun"},{"key":"1123_CR21","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1182\/blood.2023020079","volume":"142","author":"ES Hellstrom-Lindberg","year":"2023","unstructured":"Hellstrom-Lindberg ES, Kroger N. Clinical decision-making and treatment of myelodysplastic syndromes. Blood. 2023;142:2268\u201381. https:\/\/doi.org\/10.1182\/blood.2023020079","journal-title":"Blood"},{"key":"1123_CR49","doi-asserted-by":"publisher","first-page":"e8888","DOI":"10.1371\/journal.pone.0008888","volume":"5","author":"Y Huang","year":"2010","unstructured":"Huang Y, Pastor WA, Shen Y, Tahiliani M, Liu DR, Rao A. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS ONE. 2010;5:e8888. https:\/\/doi.org\/10.1371\/journal.pone.0008888","journal-title":"PLoS ONE"},{"key":"1123_CR39","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1182\/bloodadvances.2020003508","volume":"5","author":"AM Hunter","year":"2021","unstructured":"Hunter AM, Komrokji RS, Yun S, Al Ali N, Chan O, Song J, Hussaini M, Talati C, Sweet KL, Lancet JE, et al. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021;5:1017\u201328. https:\/\/doi.org\/10.1182\/bloodadvances.2020003508","journal-title":"Blood Adv"},{"key":"1123_CR17","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/sj.leu.2403805","volume":"19","author":"M Iwai","year":"2005","unstructured":"Iwai M, Kiyoi H, Ozeki K, Kinoshita T, Emi N, Ohno R, Naoe T. Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 2005;19:1367\u201375. https:\/\/doi.org\/10.1038\/sj.leu.2403805","journal-title":"Leukemia"},{"key":"1123_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/j.seminhematol.2013.01.001","volume":"50","author":"H Khan","year":"2013","unstructured":"Khan H, Vale C, Bhagat T, Verma A. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Semin Hematol. 2013;50:16\u201337. https:\/\/doi.org\/10.1053\/j.seminhematol.2013.01.001","journal-title":"Semin Hematol"},{"key":"1123_CR4","doi-asserted-by":"publisher","unstructured":"Kouroukli O, Symeonidis A, Foukas P, Maragkou MK, Kourea EP. Bone marrow immune microenvironment in myelodysplastic syndromes. Cancers. 2022;14. https:\/\/doi.org\/10.3390\/cancers14225656","DOI":"10.3390\/cancers14225656"},{"key":"1123_CR44","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/ijc.27429","volume":"131","author":"TF Kraus","year":"2012","unstructured":"Kraus TF, Globisch D, Wagner M, Eigenbrod S, Widmann D, Munzel M, Muller M, Pfaffeneder T, Hackner B, Feiden W, et al. Low values of 5-hydroxymethylcytosine (5hmdC), the sixth base, are associated with anaplasia in human brain tumors. Int J Cancer. 2012;131:1577\u201390. https:\/\/doi.org\/10.1002\/ijc.27429","journal-title":"Int J Cancer"},{"key":"1123_CR23","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/cam4.2121","volume":"8","author":"K Laribi","year":"2019","unstructured":"Laribi K, Bolle D, Alani M, Ghnaya H, Besancon A, Farhi J, Mheidly K, Denizon N, de Baugier A. Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with azacitidine. Cancer Med. 2019;8:2188\u201395. https:\/\/doi.org\/10.1002\/cam4.2121","journal-title":"Cancer Med"},{"key":"1123_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-022-00402-5","volume":"8","author":"H Li","year":"2022","unstructured":"Li H, Hu F, Gale RP, Sekeres MA, Liang Y. Myelodysplastic syndromes. Nat Reviews Disease Primers. 2022;8:74. https:\/\/doi.org\/10.1038\/s41572-022-00402-5","journal-title":"Nat Reviews Disease Primers"},{"key":"1123_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/MOH.0000000000000752","volume":"30","author":"G Maggioni","year":"2023","unstructured":"Maggioni G, Della Porta MG. Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication. Curr Opin Hematol. 2023;30:30\u20137. https:\/\/doi.org\/10.1097\/MOH.0000000000000752","journal-title":"Curr Opin Hematol"},{"key":"1123_CR38","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1182\/blood-2018-06-860890","volume":"132","author":"DE Muench","year":"2018","unstructured":"Muench DE, Ferchen K, Velu CS, Pradhan K, Chetal K, Chen X, Weirauch MT, Colmenares C, Verma A, Salomonis N, et al. SKI controls MDS-associated chronic TGF-beta signaling, aberrant splicing, and stem cell fitness. Blood. 2018;132:e24\u201334. https:\/\/doi.org\/10.1182\/blood-2018-06-860890","journal-title":"Blood"},{"key":"1123_CR30","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1182\/bloodadvances.2022008521","volume":"7","author":"AEG Osman","year":"2023","unstructured":"Osman AEG, Mencia-Trinchant N, Saygin C, Moma L, Kim A, Housman G, Pozsgai M, Sinha E, Chandra P, Hassane DC, et al. Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. Blood Adv. 2023;7:1910\u20134. https:\/\/doi.org\/10.1182\/bloodadvances.2022008521","journal-title":"Blood Adv"},{"key":"1123_CR11","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616\u201327. https:\/\/doi.org\/10.1182\/blood-2013-08-518886. quiz 3699.","journal-title":"Blood"},{"key":"1123_CR46","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00441-014-1896-7","volume":"356","author":"GP Pfeifer","year":"2014","unstructured":"Pfeifer GP, Xiong W, Hahn MA, Jin SG. The role of 5-hydroxymethylcytosine in human cancer. Cell Tissue Res. 2014;356:631\u201341. https:\/\/doi.org\/10.1007\/s00441-014-1896-7","journal-title":"Cell Tissue Res"},{"key":"1123_CR25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3109\/03602532.2014.995379","volume":"47","author":"L Pleyer","year":"2015","unstructured":"Pleyer L, Greil R. Digging deep into dirty drugs - modulation of the methylation machinery. Drug Metab Rev. 2015;47:252\u201379. https:\/\/doi.org\/10.3109\/03602532.2014.995379","journal-title":"Drug Metab Rev"},{"key":"1123_CR40","doi-asserted-by":"publisher","first-page":"81926","DOI":"10.18632\/oncotarget.18477","volume":"8","author":"T Prebet","year":"2017","unstructured":"Prebet T, Cluzeau T, Park S, Sekeres MA, Germing U, Ades L, Platzbecker U, Gotze K, Vey N, Oliva E, et al. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. Oncotarget. 2017;8:81926\u201335. https:\/\/doi.org\/10.18632\/oncotarget.18477","journal-title":"Oncotarget"},{"key":"1123_CR16","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1038\/sj.leu.2404796","volume":"21","author":"K Raj","year":"2007","unstructured":"Raj K, John A, Ho A, Chronis C, Khan S, Samuel J, Pomplun S, Thomas NS, Mufti GJ. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia. 2007;21:1937\u201344. https:\/\/doi.org\/10.1038\/sj.leu.2404796","journal-title":"Leukemia"},{"key":"1123_CR10","doi-asserted-by":"publisher","first-page":"e1007108","DOI":"10.1371\/journal.pgen.1007108","volume":"14","author":"RA Risques","year":"2018","unstructured":"Risques RA, Kennedy SR. Aging and the rise of somatic cancer-associated mutations in normal tissues. PLoS Genet. 2018;14:e1007108. https:\/\/doi.org\/10.1371\/journal.pgen.1007108","journal-title":"PLoS Genet"},{"key":"1123_CR36","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1021\/ac60214a047","volume":"36","author":"A Savitzky","year":"1964","unstructured":"Savitzky A, Golay MJE. Smoothing and differentiation of data by simplified least squares procedures. Anal Chem. 1964;36:1627\u201339. https:\/\/doi.org\/10.1021\/ac60214a047","journal-title":"Anal Chem"},{"key":"1123_CR18","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2009.23.4781","volume":"28","author":"L Shen","year":"2010","unstructured":"Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncology: Official J Am Soc Clin Oncol. 2010;28:605\u201313. https:\/\/doi.org\/10.1200\/JCO.2009.23.4781","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"1123_CR8","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1038\/s41375-023-01981-2","volume":"37","author":"L Shih","year":"2023","unstructured":"Shih L, Othus M, Schonhoff K, Shaw C, Appelbaum J, Halpern AB, Becker PS, Walter RB, Estey E, Percival ME. Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms. Leukemia. 2023;37:1912\u20134. https:\/\/doi.org\/10.1038\/s41375-023-01981-2","journal-title":"Leukemia"},{"key":"1123_CR33","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1021\/ac0489420","volume":"77","author":"L Song","year":"2005","unstructured":"Song L, James SR, Kazim L, Karpf AR. Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chem. 2005;77:504\u201310. https:\/\/doi.org\/10.1021\/ac0489420","journal-title":"Anal Chem"},{"key":"1123_CR45","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nbt.1732","volume":"29","author":"CX Song","year":"2011","unstructured":"Song CX, Szulwach KE, Fu Y, Dai Q, Yi C, Li X, Li Y, Chen CH, Zhang W, Jian X, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol. 2011;29:68\u201372. https:\/\/doi.org\/10.1038\/nbt.1732","journal-title":"Nat Biotechnol"},{"key":"1123_CR9","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1182\/bloodadvances.2021004668","volume":"5","author":"A Stengel","year":"2021","unstructured":"Stengel A, Baer C, Walter W, Meggendorfer M, Kern W, Haferlach T, Haferlach C. Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. Blood Adv. 2021;5:4426\u201334. https:\/\/doi.org\/10.1182\/bloodadvances.2021004668","journal-title":"Blood Adv"},{"key":"1123_CR43","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1126\/science.1170116","volume":"324","author":"M Tahiliani","year":"2009","unstructured":"Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930\u20135. https:\/\/doi.org\/10.1126\/science.1170116","journal-title":"Science"},{"key":"1123_CR34","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1021\/ac504786r","volume":"87","author":"Y Tang","year":"2015","unstructured":"Tang Y, Zheng SJ, Qi CB, Feng YQ, Yuan BF. Sensitive and simultaneous determination of 5-methylcytosine and its oxidation products in genomic DNA by chemical derivatization coupled with liquid chromatography-tandem mass spectrometry analysis. Anal Chem. 2015;87:3445\u201352. https:\/\/doi.org\/10.1021\/ac504786r","journal-title":"Anal Chem"},{"key":"1123_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/joim.12893","volume":"286","author":"M Tobiasson","year":"2019","unstructured":"Tobiasson M, Kittang AO. Treatment of myelodysplastic syndrome in the era of next-generation sequencing. J Intern Med. 2019;286:41\u201362. https:\/\/doi.org\/10.1111\/joim.12893","journal-title":"J Intern Med"},{"key":"1123_CR32","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.3390\/cimb45050263","volume":"45","author":"G Tsekoura","year":"2023","unstructured":"Tsekoura G, Agathangelidis A, Kontandreopoulou CN, Taliouraki A, Mporonikola G, Stavropoulou M, Diamantopoulos PT, Viniou NA, Aleporou V, Papassideri I, et al. Deregulation of autophagy and apoptosis in patients with myelodysplastic syndromes: implications for disease development and progression. Curr Issues Mol Biol. 2023;45:4135\u201350. https:\/\/doi.org\/10.3390\/cimb45050263","journal-title":"Curr Issues Mol Biol"},{"key":"1123_CR7","doi-asserted-by":"publisher","first-page":"1447001","DOI":"10.3389\/fonc.2024.1447001","volume":"14","author":"E Verigou","year":"2024","unstructured":"Verigou E, Chatzilygeroudi T, Lazaris V, de Lastic AL, Symeonidis A. Immunophenotyping myelodysplastic neoplasms: the role of flow cytometry in the molecular classification era. Front Oncol. 2024;14:1447001. https:\/\/doi.org\/10.3389\/fonc.2024.1447001","journal-title":"Front Oncol"},{"key":"1123_CR27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3324\/haematol.2013.099549","volume":"99","author":"MT Voso","year":"2014","unstructured":"Voso MT, Santini V, Fabiani E, Fianchi L, Criscuolo M, Falconi G, Guidi F, Hohaus S, Leone G. Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica. 2014;99:613\u20139. https:\/\/doi.org\/10.3324\/haematol.2013.099549","journal-title":"Haematologica"},{"key":"1123_CR26","doi-asserted-by":"publisher","first-page":"5495","DOI":"10.1158\/0008-5472.CAN-05-2385","volume":"66","author":"AS Yang","year":"2006","unstructured":"Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, et al. DNA methylation changes after 5-aza-2\u2019-deoxycytidine therapy in patients with leukemia. Cancer Res. 2006;66:5495\u2013503. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2385","journal-title":"Cancer Res"},{"key":"1123_CR24","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1182\/blood-2017-10-811729","volume":"131","author":"AM Zeidan","year":"2018","unstructured":"Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood. 2018;131:818\u201321. https:\/\/doi.org\/10.1182\/blood-2017-10-811729","journal-title":"Blood"},{"key":"1123_CR31","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1182\/blood-2023-180765","volume":"142","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Fenaux P, Han X, James DA, Malek K, Marques Ramos P, Miyazaki Y, Platzbecker U. Molecular measurable residual disease (MRD) clearance (\u2264\u20091%) is associated with improved clinical outcomes in patients with higher-risk myelodysplastic neoplasms (HR-MDS): an exploratory analysis of stimulus-MDS1 in patients receiving sabatolimab or Placebo\u2009+\u2009Hypomethylating Agent (HMA). Blood. 2023;142:3236\u20133236. https:\/\/doi.org\/10.1182\/blood-2023-180765","journal-title":"Blood"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01123-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-025-01123-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01123-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T18:48:07Z","timestamp":1739558887000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-025-01123-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1123"],"URL":"https:\/\/doi.org\/10.1186\/s10020-025-01123-7","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"11 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients and healthy participants provided their written informed consent according to the Declaration of Helsinki, being informed about both clinical and translational investigations and the study was approved by the University General Hospital of Patras Ethics Committee (approval number 33807\/24.12.2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors contributed to the article and approved the submitted version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}